About 100 reports

  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Industry Structure

Cobamamide is one important Blood Disease Drugs in China.

  • Blood Disease
  • China
  • Eisai Co., Ltd.
  • Roche Pharmaceutical Co., Ltd
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • BLOOD DISEASE DRUGS
  • Demand of Blood Disease Drugs by Region

Cobamamide is one important Blood Disease Drugs in China.

  • Blood Disease
  • China
  • Demand
  • Eisai Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Blood Disease Drugs Imports
  • Other Blood Disease Drugs

In 2009, Inosine import contribution to Blood Disease Drugs was ##. ##% while the figure was ##% in 2014 and ##. ##% in 2019.

  • Blood Disease
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

AFTER DONATION, EACH UNIT OF DONATED BLOOD IS REQUIRED TO UNDERGO A SERIES OF TESTS FOR INFECTIOUS DISEASES, INCLUDING: ##.

  • Blood Disease
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

ONE STUDY, " REDUCING BLOOD SAMPLING FOR CIRCULATING BLOOD VOLUME DETERMINATION: A PILOT FEASIBILITY, " SHOWED A ##% AGREEMENT IN CRITICALLY-ILL COHORTS WHOSE BLOOD VOLUMES WERE COMPARED USING ONE BLOOD DRAW VERSUS FIVE BLOOD DRA

  • Blood Disease
  • Clinical Trial
  • Company
  • Company Financials
  • Demand
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • NOV 02, 2018: NOVARTIS TO PRESENT NEW DATA ON CRIZANLIZUMAB AT 2018 ASH ANNUAL MEETING
  • (SPARTAN). The trial was registered with the U.S. National Institutes of Health.

Blood tests revealed her pain stemmed from a form of sickle cell disease.

  • Blood Disease
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • DEC 05, 2017: ITALFARMACO ANNOUNCES GIVINOSTAT CLINICAL TRIAL PRESENTATIONS AT THE 59TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
  • DEC 11, 2017: ITALFARMACO PRESENTS POSITIVE PHASE II STUDY RESULTS FOR GIVINOSTAT IN POLYCYTHEMIA VERA PATIENTS AT THE ASH ANNUAL MEETING

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Lung Cancer
  • United States
  • Product Initiative
  • Incyte Corporation
  • AUG 01, 2019: HEALTH MINISTRY TO REIMBURSE NOVARTIS' REVOLADE TREATING SEVERE APLASTIC ANEMIA
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

People with the disease have abnormally low levels of platelets in the blood.

  • Blood Disease
  • Hospital
  • United States
  • Product Initiative
  • BioLineRx Ltd.
  • US: COAGULATION ANALYZERS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 10.2 NORTH AMERICA

THE DIVISION OF BLOOD DISEASES AND RESOURCES (DBDR), A PART OF THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI), SUPPORTS RESEARCH ON BLOOD DISEASES SUCH AS ANEMIA, SICKLE-CELL DISEASE, AND THALASSEMIA.

  • Blood Disease
  • Medical Device
  • North America
  • United States
  • Sysmex Corporation
  • HEMOPURIFIER - PRODUCT DESCRIPTION

The company develops biomimetic blood perfusion devices for disease prevention or management.

  • Blood Disease
  • Blood Supply
  • Clinical Trial
  • Hospital
  • CytoSorbents Corporation
  • BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2018-2025 (USD MILLION)
  • ARTICLES PUBLISHED ON BIOSIMILARS FOR BLOOD DISORDERS, 2010-2018

This segment includes ailments such as anemia, bleeding disorders, and blood clot disease.

  • Biosimilar
  • Blood Disease
  • North America
  • United States
  • Market Size
  • NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 11.2 NORTH AMERICA

THE DIVISION OF BLOOD DISEASES AND RESOURCES (DBDR), A PART OF THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI), SUPPORTS RESEARCH ON BLOOD DISEASES SUCH AS ANEMIA, SICKLE-CELL DISEASE, AND THALASSEMIA.

  • Blood Disease
  • In Vitro Diagnostics
  • North America
  • United States
  • Sysmex Corporation
  • Jun 06, 2019: FDA agrees to review Celgene-Acceleron's luspatercept in anaemia
  • Apr 26, 2019: Celgene and Acceleron Pharma announce submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

One pediatric patient is still receiving regular blood transfusions.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Additional Areas in Sickle Cell Disease Date and Time: Thursday, October ##, 2017, ##:##-##:## p. m.

  • Blood Disease
  • Therapy
  • World
  • Company Operations
  • Roche Group
  • Sep 06, 2018: Protagonist Therapeutics issues U.S. patent for PTG-300

The molecules developed by companies in Phase II, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Blood Disease
  • United States
  • World
  • Product Initiative
  • Daiichi Sankyo Company
  • with the U.S. National Institutes of Health.
  • ELTROMBOPAG OLAMINE - DRUG PROFILE

The Karius test for infectious diseases detects microbial cell-free DNA (cfDNA) in plasma from more than a thousand pathogens from a single blood draw in one day using NGS, including bacteria, DNA viruses, fungi and protozoa.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Pluristem Therapeutics Inc.
  • 7.1 OVERVIEW

', Blood advances.

  • Blood Disease
  • Novo Nordisk Group
  • Pfizer Inc.
  • Roche Group
  • Takeda Pharmaceutical Company Limited
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • The content of this press release is solely the views of its authors and does not represent the official views of the National Institutes of Health.

May ##, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases Rivella and colleagues published their study online today in the journal Blood.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Jan 09, 2020: New England journal of medicine publishes results of pivotal phase 3 Reblozyl (luspaterceptaamt) MEDALIST trial
  • FEATURED NEWS & PRESS RELEASES

In addition, treatment with ACE-## corrected anemia in animal models of chronic kidney disease and acute blood loss.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
  • LUSPATERCEPT - DRUG PROFILE

ACE-## is being evaluated in two Phase II trials, one in facioscapulohumeral muscular dystrophy (FSHD) and one in CMT disease.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.
  • AUG 01, 2019: HEALTH MINISTRY TO REIMBURSE NOVARTIS' REVOLADE TREATING SEVERE APLASTIC ANEMIA
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

People with the disease have abnormally low levels of platelets in the blood.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • BioLineRx Ltd.
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

" In the Spanish Phase ## trial, RP-L## has shown strong safety and promising efficacy to date, with durable engraftment in peripheral blood and bone marrow.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Boehringer Ingelheim GmbH

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • BIOMARKER ASSAY - POLYCYTHEMIA VERA - PRODUCT DESCRIPTION

The simple blood test lets doctors diagnose genetic disorders in fetuses early in pregnancy by sequencing small amounts of DNA in the mother' s and the father' s blood.

  • Blood Disease
  • Cancer
  • Clinical Trial
  • United States
  • Company
  • BIOMARKER ASSAY - SEPSIS - PRODUCT DESCRIPTION

Liquid biopsy: Detection of cancer or other diseases by testing bodily fluids such as blood.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • Medical Device
  • Grifols, S.A.

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • 5. All the trials included are unique trials.

Hoffmann-La Roche Ltd ## Jul 2018 ## Jul 2033 ## ## New York Blood Center National Cord Blood Program New York Blood Center National Cord Blood Program GDCT## NCT##, ## Hematological Disorders Anemia, Aplastic Anemia, Leukemia, Lymphoma

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • Leukemia
  • Novartis AG
  • 5. All the trials included are unique trials.

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Autoimmune Disease
  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • World
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones

Protagonist is developing PTG-## for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative